Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma
- 31 December 1994
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 30 (2), 167-170
- https://doi.org/10.1016/0959-8049(94)90080-9
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: Preliminary resultsEuropean Journal Of Cancer, 1993
- Editorial: Treatment for patients with hepatocellular carcinoma; state-of-the-artAnnals Of Oncology, 1992
- Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2European Journal of Cancer and Clinical Oncology, 1991
- Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial.Journal of Clinical Oncology, 1991
- Phase II trial of buserelin in hepatocellular carcinomaEuropean Journal of Cancer and Clinical Oncology, 1989
- Continuous infusion recombinant interleukin-2 (rIL-2) in adoptive cellular therapy of renal carcinoma and other malignanciesCancer Treatment Reviews, 1989
- Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinomaCancer Treatment Reviews, 1989
- Lysis of primary hepatic tumours by lymphokine activated killer cells.Gut, 1987
- Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cellsCancer, 1986
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982